Directors, Metabolic Profiling Forum

Dr Julian Griffin

Dr Julian L. Griffin is a University Senior Lecturer at the Department of Biochemistry, Cambridge and a group leader at the Medical Research Council HNR. He is also a group leader in the Cambridge Systems Biology Centre and a PI at the MRC Centre for Obesity and Related Disorders. A chemist by first degree, he gained his D. Phil in Biochemistry with Prof. Sir George Radda studying brain metabolism using 13C NMR spectroscopy. He held a Harvard Medical school/ Massachusetts General Hospital fellowship with Prof. Doug Lewandowski, studying cardiac metabolism by 13C NMR before joining Prof. Jeremy Nicholson’s group at Imperial College London as a NERC postdoctoral fellow and then Royal Society University Research Fellow. He is developing NMR and mass spectrometry based metabolomic tools for identifying metabolic biomarkers associated with disease, drug toxicity and understanding the control of metabolic pathways. He also has wide experience in multivariate statistical processes required to process the data. In addition he has used stable isotopes to follow metabolic fluxes both in vitro and in vivo. He is a chair of a sub-committee of the Metabolomic Standards Initiative which aims to define the information required to describe a metabolomic experiment. He is also the secretary to the Metabolomic Society and has co-organized a number of the Metabomeeting conferences of which he is a co-founder. He is on the editorial board of Biomarkers and Genome Medicine. He teaches chemistry, biochemistry and systems biology to undergraduates. Jules reviews for a number of charitable and government grant giving bodies, particularly if it involves travelling to places with snow or sun, neither of which are in plentiful supply in Cambridge.

Professor Roy Goodacre

Roy Goodacre is Professor of Biological Chemistry at the University of Manchester. His research interests are broadly within metabolomics, analytical biotechnology and systems and synthetic biology. He has over 20 years experience of advanced bioanalytical measurements including MS-based metabolomics and has pioneered the application of a variety of Raman spectroscopy methods for the direct analysis of bacteria, eukaryotic cells and human biofluids. He has published >360 scientific papers, and if you believe in such metrics has reasonably healthy H-indices (61, Web of Science; 76, Google Scholar).

He helped established the Metabolomics Society in 2005 and remained as a director until 2015. He joined the directorship of the Metabolic Profiling Forum in 2008. He is also founding Editor-in-Chief of Metabolomics (established 2005), as well as being on the Editorial Advisory Boards of four other analytical journals. He is founding director of a novel microbial resistance typing diagnostics company Spectromics (www.spectromics.com). Finally, he was awarded the RSC Industrially-Sponsored Award in Bioanalytical Chemistry in 2005, made a Fellow of the Society for Applied Spectroscopy in 2015, an Honorary Fellow of the Metabolomics Society in 2016, and elected as a Fellow of the Learned Society of Wales in 2017.

Dr Reza Salek

Dr Salek got his PhD in Molecular Biophysics and Biochemistry from University College London, UK. He started working in the field of metabolomics in the University of Cambridge, over time moving from lab experimental settings towards data analysis and data handling. In the past, he has worked as scientific investigator at the Medical Research Council, Cambridge UK. In 2012, he joined EMBL-EBI and currently working as the Scientific Coordinator. EMBL-EBI  hosts the MetaboLights (http://www.ebi.ac.uk/metabolights/), the first general purpose repository for metabolomics data. Open access data sharing is of paramount importance to the metabolomics community growth, enabling community to move a step closer to the result reproducibility, a key objective for any scientific field. Here metabolomics standards can play a vital role (http://www.metabolomics-msi.org). Dr. Salek has managed and coordinated a large EU infrastructure project on metabolomics data standards, COSMOS (Coordination of Standards in Metabolomics - http://cosmos-fp7.eu/), it has re-ignited standards effort within community leaders, in a more bottom-up approach. Such efforts combined with data sharing in MetaboLights, would benefit the community substantially. Professionally, Dr Salek is on baord of Directors of the Metabolomics Scoety, member of the Cambridge Systems Biology Centre. He is the main organiser of the “EMBO Practical Course on Metabolomics Bioinformatics for Life Scientists 2012
 - 2017" He is also associate Editor for Frontiers Metabolomics Journal.

Dr Andy Southam

Dr Andy Southam is a Research Fellow in mass spectrometry metabolomics and lipidomics with over 10 years’ experience in this field. He is actively involved in the development of mass spectrometry metabolomics and lipidomics methods. The biological aspect of his work focuses on cancer metabolism, in particular, the role of lipid metabolism in cancer. This aspect of his work aims to enhance early cancer detection, understand disease mechanism and improve anticancer therapeutics. He has several publications in metabolomics / lipidomics method development and biological application including first author articles in Nature Protocols and Cancer Research. He has been awarded project grants – including an award from the Wellcome Trust – to further his research. Andy gained his PhD with Prof Mark Viant at University of Birmingham in 2009 where he characterised liver cancer metabolism in flatfish using NMR and mass spectrometry metabolomics. He then undertook a Postdoc position as the metabolomics lead in a translational lab whose aim was to improve and develop therapeutics for blood cancers. In 2017 he was appointed as a Research Fellow in Metabolomics and Lipidomics at Phenome Centre Birmingham working with Dr Rick Dunn. Here he works as a mass spectrometry analyst, while also pursuing his own research interest in cancer metabolism.

Dr Dong-Hyun Kim

Dr Dong-Hyun Kim is an Assistant Professor and co-leader of Centre for Analytical Bioscience in the School of Pharmacy, the University of Nottingham. Prior to this position he conducted postdoctoral research on clinical metabolomics of trypanosomes in Glasgow Biomedical Research Centre at the University Glasgow after four years in the School of Chemistry at the University of Manchester obtaining his PhD, which involved applications of analytical instruments such as FT-IR, Raman spectroscopy and mass spectrometry for the investigation of cervical cancer. His research career has focused on the advancement and application of mass spectrometry (MS)-based metabolomics methods in order to investigate complex biological and/or clinical problems. He has been particularly interested in employing isotopically labelled compounds to enable accurate metabolic pathway analysis and to enhance the reproducibility and quantitation of MS-based methods including untargeted metabolite profiling and ambient surface analysis. He teaches chemistry, drug delivery and medical diagnostics on Master of Pharmacy and Master of Science in Pharmaceutical Sciences.

 

Past Directors

Dr John Haselden

Dr John Haselden is currently Head of the Department of Investigative Preclinical Toxicology and a director within Safety Assessment at GSK based in Ware, Herts. He has worked in the pharmaceutical industry (GSK and its heritage companies) since completion of his PhD in lipid biochemistry and drug metabolism at the University of London. He has worked predominantly as a regulatory toxicologist and project manager over the last 16 years, although for the last 10 years has been responsible for evaluating and developing GSK’s worldwide capability to carry out metabolic profiling work in support of numerous research initiatives and various drug development projects. He serves on a number of editorial boards and external bodies related to Safety Biomarkers (ABPI & EfPIA), Stem Cells for Safer Medicines, and as a scientific advisor on Omics and Predictive Toxicology programs under the Framework and IMI banners. He was the instigator and a co-founder of the Metabolic Profiling Forum.

Dr Andy Nicholls

As part of Jeremy Nicholson’s team, Dr Andy Nicholls obtained his PhD from the University of London and was instrumental in a proof of principal hepatoxocity model based on metabolomics data with GlaxoWellcome that led to the establishment of the Consortium on Metabonomic Toxicology (COMET) at Imperial College London. Following further studies into the application of metabolomics as a senior postdoctoral fellow (supported by Merck, Sharpe and Dohme) he became an associate director for Metabometrix Ltd, a biotechnology spin-out company from Imperial College London. This role led to him taking a senior research position at GlaxoSmithKline where he now heads the Biochemistry and In Vitro toxicology groups in the investigative arm of Safety Assessment.His principal areas of research involve the study of metabolic alterations in complex, multicellular organisms and the determination of the root-cause mechanisms of drug-induced toxicity.

Andy was a co-founder of the Metabolic Profiling Forum, a not-for-profit organisation that runs the International Metabomeeting conference series and supports the attendance of students at scientific conferences. With collaborators he was instrumental in the inception of the standardisation practises for metabolomics (now the Metabolomics Standards Initiative) and remains actively involved in the continuation of this work. From 2010 he was elected to the position of President of the SMASH organization running the highly successful International SMASH NMR conference, of which he was also co-chair in 2007 & 2009.  Andy also regularly acts an expert reviewer for a range of peer-reviewed publications and both charitable and governmental institutions.  He also represents GlaxoSmithKline on a number of external metabolomics collaborations, most recently the Human Serum Metabolome (HUSERMET) project with the University of Manchester, UK.